Добірка наукової літератури з теми "Nineteen thirty-seven, A.D., in art"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Зміст
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Nineteen thirty-seven, A.D., in art".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Nineteen thirty-seven, A.D., in art"
1
Gill, K. S., E. L. Lubbers, B. S. Gill, W. J. Raupp, and T. S. Cox. "A genetic linkage map of Triticum tauschii (DD) and its relationship to the D genome of bread wheat (AABBDD)." Genome 34, no. 3 (June 1, 1991): 362–74. http://dx.doi.org/10.1139/g91-058.
Повний текст джерелаАнотація:
One hundred and seventy-eight loci have been mapped in Triticum tauschii (Coss.) Schmal. (2n = 14, DD) and Triticum aestivum L. em. Thell. (2n = 42, AABBDD). Thirty-five loci were mapped by aneuploid analysis in T. aestivum. One hundred and fifty-two loci, including 143 restriction fragment length polymorphisms (RFLPs), 8 proteins, and 1 leaf rust resistance gene, were mapped in an F2 population (60 plants) of T. tauschii. One hundred and twenty-seven loci were placed in linkage groups belonging to seven D-genome chromosomes of T. tauschii. The source of the probes was a PstI genomic library of T. tauschii, which gave 13% single-low copy clones. Four restriction endonucleases (DraI, EcoRI, EcoRV, HindIII) gave 75% polymorphism between the two parents. Nineteen clones detected multiloci ranging from two to nine in number. Deletions–insertions and point mutations were equally important for generating RFLPs. A hypervariable sequence was identified, which may have potential use in varietal fingerprinting. One marker was found to be linked to a rust-resistance gene. The map will be useful for determining genetic relationships in the Triticeae and for tagging genes of economic importance.Key words: restriction fragment length polymorphism, Triticum aestivum, leaf rust, isozymes, Aegilops squarrosa.
2
Graham, M. L., J. E. Herndon, J. R. Casey, S. Chaffee, G. H. Ciocci, J. P. Krischer, J. Kurtzberg, et al. "High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors." Journal of Clinical Oncology 15, no. 5 (May 1997): 1814–23. http://dx.doi.org/10.1200/jco.1997.15.5.1814.
Повний текст джерелаАнотація:
PURPOSE We treated 49 patients with recurrent or poor-prognosis CNS malignancies with high-dose chemotherapy regimens followed by autologous marrow rescue with or without peripheral-blood stem-cell augmentation to determine the toxicity of and event-free survival after these regimens. PATIENTS AND METHODS Nineteen patients had medulloblastomas, 12 had glial tumors, seven had pineoblastomas, five had ependymomas, three had primitive neuroectodermal tumors, two had germ cell tumors, and one had fibrosarcoma. Thirty-seven received chemotherapy with cyclophosphamide 1.5 g/m2 daily x 4 and melphalan 25 to 60 mg/m2 daily x 3. Nine received busulfan 37.5 mg/m2 every 6 hours x 16 and melphalan 180 mg/m2 (n = 7) or 140 mg/m2 (n = 2). Three received carboplatin 700 mg/m2/d on days -7, -5, and -3 and etoposide 500 mg/m2/d on days -6, -4, and -2. All patients received standard supportive care. RESULTS Eighteen of 49 patients survive event-free 22+ to 55+ months (median, 33+) after transplantation, including nine of 16 treated before recurrence and nine of 33 treated after recurrence. There was one transplant-related death from pulmonary aspergillosis. Of five patients assessable for disease response, one had a partial remission (2 months), one has had stable disease (55+ months), and three showed progression 2, 5, and 8 months after transplantation. CONCLUSION The toxicity of these regimens was tolerable. Certain patients with high-risk CNS malignancies may benefit from such a treatment approach. Subsequent trials should attempt to determine which patients are most likely to benefit from high-dose chemotherapy with autologous stem-cell rescue.
3
Agamy, Emad Mohamed Tolba Mahmoud, and Wilhelm Niedermeier. "Indirect Sinus Floor Elevation for Osseointegrated Prostheses. A 10-Year Prospective Study." Journal of Oral Implantology 36, no. 2 (April 1, 2010): 113–21. http://dx.doi.org/10.1563/aaid-joi-d-09-00085.
Повний текст джерелаАнотація:
Abstract The aim of this study was to evaluate the indirect/closed maxillary floor elevation technique for the insertion of osseointegrated implants to support fixed prostheses clinically. Thirty-one patients (19 female, 12 male) with a mean age of 62 ± 9 years were selected for this study. All patients needed implants in the posterior maxillary region to support osseointegrated prosthesis. Forty-seven implants were inserted using the indirect/closed sinus floor elevation method, and another 31 implants were placed in the same individuals as intra-individual control. No augmentation material was used along with implantation. The mean bone height before sinus lift was 9.78 ± 1.68 mm (minimum 5.6 mm), and for controls it was 15.62 ± 3.44 mm. The average length of the implants used was 12.00 ± 1.70 mm, whereas for controls it was 13.39 ± 1.60 mm. The patients were recalled for periodic checkups every 6 months, and the radiographic controls were made every 12 months. One control fixture failed after uncovering; 77 implants were loaded, and 5 of them failed (2 controls and 3 of the sinus lift group) between 3 and 59 months following loading. One hundred nineteen months after surgery (112 months following loading), the censored survival rate (Kaplan-Meier) was 93.6% for sinus lift implants and 90.3% for controls. The crestal bone level changes were not significant either before loading or after loading for both sinus lift and control implants. None of the remaining implants showed any signs of mobility or peri-implant disease, and none of the patients exhibited sinus problems during the entire observation period.
4
Kubiak, Katarzyna, Maria Karolina Szmidt, Joanna Kaluza, Agnieszka Zylka, and Ewa Sicinska. "Do Dietary Supplements Affect Inflammation, Oxidative Stress, and Antioxidant Status in Adults with Hypothyroidism or Hashimoto’s Disease?—A Systematic Review of Controlled Trials." Antioxidants 12, no. 10 (September 24, 2023): 1798. http://dx.doi.org/10.3390/antiox12101798.
Повний текст джерелаАнотація:
This systematic review aims to summarise the results of controlled trials on dietary supplements (DS) usage and inflammation, oxidative stress, antioxidant status, and thyroid parameter improvement in hypothyroidism (HT)/Hashimoto’s thyroiditis (AIT) patients. The study protocol was registered with PROSPERO (no. CRD42022365149). A comprehensive search of the PubMed, Scopus, and Web of Science databases resulted in the identification of nineteen randomised controlled trials and three non-randomised studies for the review; three studies examined the effect of supplementation with vitamin D, twelve studies—with selenium, and seven studies—with other DS. Based on very limited evidence, the lack of influence of vitamin D supplementation on inflammatory parameters was found, while no studies have examined oxidative stress and antioxidant status parameters, and only one provided results for a single thyroid parameter after an intervention. Some evidence was found proving that selenium supplementation may decrease inflammation and improve thyroid parameters, but reaching a conclusion about its influence on oxidative stress and antioxidant status is not possible because of the insufficient number of studies. Additionally, due to examining other DS (e.g., multicomponent, Nigella sativa, and genistein) only in single studies, conclusions cannot be drawn. Further long-term, high-quality randomised controlled trials are necessary to better understand the influence of DS on inflammation, oxidative stress, and antioxidant status, as well as their potential to improve thyroid gland function in HT/AIT patients.
5
Nivedita, ,., Praveen C. Sobti, and Sandeep Kaushal. "SAFETY, EFFICACY AND TOLERABILITY OF INTRAVENOUS ANTI-D IMMUNOGLOBULIN IN NEWLY DIAGNOSED IMMUNE THROMBOCYTOPENIA IN CHILDREN." International Journal of Medical Sciences and Pharma Research 1, no. 2 (April 15, 2015): 8–15. http://dx.doi.org/10.22270/ijmspr.v1i2.6.
Повний текст джерелаАнотація:
Objectives: To evaluate the effect of single dose (75 µg/kg) Anti-D in children with newly diagnosed immune thrombocytopenia in terms of its safety, efficacy and tolerability. Methods: This was a prospective study conducted in Dayanand Medical College and Hospital-a tertiary care hospital over a period of 18 months. In this study, nineteen children with newly diagnosed immune thrombocytopenia (10 males, 9 females) were included. Mean age of the children was 4.7 ± 3.2 years. Anti-D was administered as a single intravenous injection in a dose of 75 µg/kg. Main outcome variables taken were Increase in platelet count, fall in hemoglobin, change in AST, ALT, urea, creatinine, sodium and potassium levels and appearance of any adverse symptom. Results: The response rate to Anti-D was 89.4% (n = 17). Mean increase in platelet count was 125.5 ± 86.2 x 109 /L at 48 h and 257.5 ± 176.4 x 109 /L at day seven. Response at 48 h was seen in 88.2% of the children. Females showed a better response than males (p = 0.05). Anti-D did not have any significant effect on renal or liver function tests and it caused a mean fall of 1.76 ± 1.06 g/dL in hemoglobin. Mild adverse effects developed in 52% children which resolved spontaneously within 12 h. Conclusion: Anti-D shows a good response (89.4%) in children with newly diagnosed ITP with an acceptable safety profile. Adverse effects like fever and chills are common (52%).
6
Smith, Ley Cody, Alessandro Venosa, Andrew J. Gow, Helmut Zarbl, Jeffrey D. Laskin, and Debra L. Laskin. "Macrophage Activation in the Lung during the Progression of Nitrogen Mustard Induced Injury is Associated with Altered miRNA Expression." Journal of Immunology 206, no. 1_Supplement (May 1, 2021): 97.16. http://dx.doi.org/10.4049/jimmunol.206.supp.97.16.
Повний текст джерелаАнотація:
Abstract Activated macrophages have been implicated in lung injury and fibrosis induced by the cytotoxic alkylating agent, nitrogen mustard (NM). Accumulating evidence suggests that phenotypic activation of macrophages during initiation, progression, and resolution of inflammatory responses is regulated by groups of miRNAs that act in concert to coordinate cellular activity. Herein, we determined if macrophage activation after NM injury was associated with altered miRNA expression. Male rats were exposed to NM (0.125 mg/kg, i.t.) and PCR array analysis of miRNAs involved in inflammation and fibrosis was performed in alveolar macrophages recovered from bronchoalveolar lavage. Results revealed unique and overlapping miRNA expression profiles in macrophages isolated 1, 3, 7, and 28 d post-NM. Seven miRNAs were upregulated in macrophages throughout the time-course, while three miRNAs were uniquely expressed 1 d post-NM, six at 3 d, six at 7 d, and nineteen at 28 d. Linkage with macrophage RNA-seq data showed differentially expressed miRNAs regulated mRNAs involved in STAT3, IL-6 and iNOS inflammatory signaling pathways at 1 d, and IL-4, PPAR and Sirtuin signaling at 28 d post-NM. Ingenuity Pathway Analysis predicted miR-21-5p, miR-29, miR-26a, miR-34a and let-7a as key regulators of macrophage mobilization, activation, and lipid homeostasis after NM. Collectively, these data show that NM promotes alterations in miRNA expression linked to lung macrophage responses during inflammatory injury and fibrosis. These findings provide clues on pathways regulating macrophage activation and may help identify novel therapeutic targets. This work was supported by NIH grants AR055073, ES004738, HL086621, ES005022, ES030984, and ES007148.
7
Shah, Gaurav D., Joachim Yahalom, Denise D. Correa, Rose K. Lai, Jeffrey J. Raizer, David Schiff, Renato LaRocca, Barbara Grant, Lisa M. DeAngelis, and Lauren E. Abrey. "Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma." Journal of Clinical Oncology 25, no. 30 (October 20, 2007): 4730–35. http://dx.doi.org/10.1200/jco.2007.12.5062.
Повний текст джерелаАнотація:
Purpose Our goals were to evaluate the safety of adding rituximab to methotrexate (MTX)-based chemotherapy for primary CNS lymphoma, determine whether additional cycles of induction chemotherapy improve the complete response (CR) rate, and examine effectiveness and toxicity of reduced-dose whole-brain radiotherapy (WBRT) after CR. Patients and Methods Thirty patients (17 women; median age, 57 years; median Karnofsky performance score, 70) were treated with five to seven cycles of induction chemotherapy (rituximab, MTX, procarbazine, and vincristine [R-MPV]) as follows: day 1, rituximab 500 mg/m2; day 2, MTX 3.5 gm/m2 and vincristine 1.4 mg/m2. Procarbazine 100 mg/m2/d was administered for 7 days with odd-numbered cycles. Patients achieving CR received dose-reduced WBRT (23.4 Gy), and all others received standard WBRT (45 Gy). Two cycles of high-dose cytarabine were administered after WBRT. CSF levels of rituximab were assessed in selected patients, and prospective neurocognitive evaluations were performed. Results With a median follow-up of 37 months, 2-year overall and progression-free survival was 67% and 57%, respectively. Forty-four percent of patients achieved a CR after five or fewer cycles, and 78% after seven cycles. The overall response rate was 93%. Nineteen of 21 CR patients received the planned 23.4 Gy WBRT. The most commonly observed grade 3 to 4 toxicities included neutropenia (43%), thrombocytopenia (36%), and leukopenia (23%). No treatment-related neurotoxicity has been observed. Conclusion The addition of rituximab to MPV increased the risk of significant neutropenia requiring routine growth factor support. Additional cycles of R-MPV nearly doubled the CR rate. Reduced-dose WBRT was not associated with neurocognitive decline, and disease control to date is excellent.
8
Jamal, Jazmi Izwan, Mohd Hafizuddin Mohd Yusof, Kok Yoong Lim, and Jamia Azdina Jamal. "Improving Visual Style Classification in Digital Games Using Intercoder Reliability Assessment." Journal of Information and Communication Technology 22, no. 2 (April 3, 2023): 283–308. http://dx.doi.org/10.32890/jict2023.22.2.6.
Повний текст джерелаАнотація:
The digital gaming community appreciates visual style information in digital games as it facilitates information seeking. Nevertheless, learned scholars have discovered that the digital game visual style classification is inconsistent and easily modified, potentially limitingthe information and leading to inaccurate visual terminologies during information discovery. Therefore, this cross-sectional study wasperformed to assess multiple visual style classification terms and their definitions among Malaysian game developers using the closedcard sorting exercise. A total of seven professional game developers participated in an online survey that comprised thirty-five digital game case studies using a card sorting technique. They were asked to classify nineteen visual style classification terms, including psychedelic, text, illusionism, photorealism, televisualism, handicraft, caricature, celshaded, comic book (anime), watercolour, Lego, minimalism, pixel art, silhouette, bright, dark, maplike, colourful, and black and white. The Fleiss’ kappa intercoder reliability assessment was performed to measure the coders’ agreement on visual style classification, followed by the think-aloud protocol descriptive analysis to gather assessment insights into the visual style descriptions. The intercoder reliability test achieved a significantly moderate agreement based on the results. The professional game developers agreed on eighteen visual stylesand rejected the bright visual style classification due to its overlapping description with the colourful visual style. The definition of ten visual style classifications was improved from the existing Video Game Metadata Schema (VGMS) description, contributing to the digital game’s coherence and consistency. This improvement will enhance visual style classification information for machine-learning-based recommendation systems for digital game distribution platforms and digital archiving.
9
Karzai, Fatima H., Ravi Amrit Madan, Andrea Borghese Apolo, Yangmin M. Ning, Howard L. Parnes, Philip M. Arlen, Melony A. Beatson, et al. "Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations in metastatic castrate resistant prostate cancer (mCRPC)." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e16017-e16017. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e16017.
Повний текст джерелаАнотація:
e16017 Background: We have completed accrual of 63 patients (pts) to our study combining lenalidomide (L), with bevacizumab (B), docetaxel (D), and prednisone (P) (ART-P) in mCRPC. Due to the lack of improved survival and the increased toxicity of anti-angiogenic docetaxel combinations in the MAINSAIL and CALGB 90401 trials, we attempted to compare and contrast our studies with these failed phase III trials. Methods: Among the first 52 pts on ART-P, 3 received L 15 mg daily, 3 received 20 mg daily, and the others received 25 mg daily for 14 days of every 21−day cycle (C). We then enrolled 11 pts at L 15 mg. All pts received D 75 mg/m2 and B 15 mg/kg on day 1 with P 10 mg and enoxaparin daily. Pegfilgrastim was given on day 2. Patients on CALGB 90401 received D 75 mg/m2 and B 15 mg/kg on day 1, with P 10 mg. On MAINSAIL, pts received D 75 mg/m2, L 25 mg daily for 14 days of every 21−day cycle with daily P. Patients on CALGB 90401 and MAINSAIL did not receive enoxaparin or pegfilgrastim prophylactically. Results: The median number of Cs on ART-P is 18 (1-52). Median PFS is 19.1 months. Twenty-seven pts had a PR, and one pt with measurable disease had a CR. Two patients (3%) had deep vein thromboses. Of 1,334 Cs given, 14 cycles were complicated by febrile neutropenia (FN) (1%). There were no treatment related deaths. In comparison, median number of Cs in MAINSAIL L+DP arm was 6, with a PFS of 45 weeks and an OS of 77 weeks. Thirty-four pts (6.5%) developed pulmonary emboli and there were 2 deaths due to toxicity in the experimental arm. Nearly 12% of Cs were complicated by FN. In the experimental arm of CALGB 90401 trial, median OS was 22.6 months with median PFS of 9.9 months. The median number of Cs were 8 and 19 pts developed thrombosis/emboli (3.6%). In addition, 37 patients developed FN and treatment related deaths were reported at 4%. Conclusions: The use of supportive care allowed longer treatment duration with the ART-P combination as compared to D+L (MAINSAIL) and D+B (CALGB 90401), potentiating a longer PFS, RR and possibly OS with an improved safety profile. This data demonstrates the potential importance of supportive measures and is hypothesis generating for future combination studies. Clinical trial information: NCT00942578.
10
Androulakis, Nikos, Charalambos Kourousis, Meletios A. Dimopoulos, George Samelis, Stelios Kakolyris, Nikos Tsavaris, Kostas Genatas, et al. "Treatment of Pancreatic Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor: A Multicenter Phase II Study." Journal of Clinical Oncology 17, no. 6 (June 1999): 1779. http://dx.doi.org/10.1200/jco.1999.17.6.1779.
Повний текст джерелаАнотація:
PURPOSE: To determine the efficacy and tolerance of single-agent docetaxel and granulocyte colony-stimulating factor in patients with advanced pancreatic cancer. PATIENTS AND METHODS: Thirty-three chemotherapy-naive patients (median age, 65 years) with histologically confirmed pancreatic cancer were treated, after appropriate premedication, with docetaxel (100 mg/m2) and granulocyte colony-stimulating factor (150 μg/m2/d subcutaneously days 2 through 10) every 3 weeks. World Health Organization performance status was 0 to 1 in 28 patients (85%) and 2 in 5 patients (15%). Twenty-nine patients had stage III and IV disease. RESULTS: One complete response (3%) and one partial response (3%) were observed for an overall response rate of 6% (95% confidence interval, 2.1% to 14.2%). Nineteen patients (58%) had stable disease and 12 (36%) had progressive disease. The duration of the two objective responses was 10 and 28 weeks, and the median time to tumor progression was 20 weeks. The median overall survival was 36 weeks. The actuarial 1-year survival was 36.4%. The performance status improved in seven of 21 assessable patients (24%) and pain improved in 14 of 21 (67%) assessable patients; five patients (29%) experienced weight gain during treatment. Disease-related asthenia, anorexia, vomiting, and diarrhea improved in 29%, 15%, 67%, and 47% of the assessable patients, respectively. Serum concentrations of CA 19-9 were decreased by more than 50% in seven patients (35%). Grade 3 and 4 neutropenia occurred in four patients (12%) and eight patients (24%), respectively, with two episodes of febrile neutropenia. There were no treatment-related deaths. Grade 3/4 asthenia occurred in three patients. CONCLUSION: Although docetaxel has a marginal objective activity in pancreatic cancer, it seems to have an important effect on tumor growth control, conferring a clinical benefit.
Книги з теми "Nineteen thirty-seven, A.D., in art"
1
Bielefeld, Kunsthalle, ed. 1937: Perfektion und Zerstörung ; [zur Ausstellung "1937. Perfektion und Zerstörung" vom 30. September 2007 bis 13. Januar 2008 in der Kunsthalle Bielefeld. Tübingen: Wasmuth, 2007.
Знайти повний текст джерела